Li, Jian - Monash University - Department of Microbiology

个人简介

Professor Jian Li (PhD 2002) is an elected Fellow of the American Academy of Microbiology and Head of the Antimicrobial Systems Pharmacology Laboratory at the Biomedicine Discovery Institute, Monash University. He is a Web of Science Highly Cited Researcher in Pharmacology & Toxicology (2015 - 2017). Dr Li has an internationally recognised track record in the pharmacology of polymyxins and the discovery of novel, safer antimicrobial peptides. He has 400 publications (including 309 on polymyxins alone) with 23,466 citations and an h-index of 75. His team has developed a novel lipopeptide drug QPX9003 from concept into the clinic to target MDR Gram-negative pathogens (NIH/NIAID) and Phase-I clinical trials are conducted in the USA. The majority of modern polymyxin pharmacology data are reported by his group. His research has led to the first dosing guidelines of polymyxins which have been adopted worldwide and have significantly improved clinical practice. Dr Li's research is funded by the NIH, NHMRC, ARC, pharmaceutical companies and other grant bodies. Dr Li is an Editor of the International Journal of Antimicrobial Agents and an Associate Editor of BMC Microbiology and Frontiers in Microbiology. He is an invited reviewer for 184 international journals and grant/fellowship applications for the Australian National Health and Medical Research Council (NHMRC), Australian Research Council (ARC) and 21 international funding bodies (e.g. NIH/NIAID). Dr Li has received numerous awards, including Australian Leadership Award (2013), Australian National Health and Medical Research Council’s Ten of the Best Research Projects (2014) and Australian Academy of Science Jacques Miller Medal (2017).

研究领域

Antibiotics are a cornerstone of modern medicine and over the last century have significantly decreased mortality worldwide. Unfortunately, resistance to these ‘magic bullets’ has become one of the greatest threats to human health that the world faces, now and in the coming decades. If proactive solutions are not found to prevent widespread antibiotic resistance, it is estimated that by 2050 ~10 million people per year will die of infections. The World Health Organization (WHO) has urged all government sectors and society to act on antimicrobial resistance (AMR). In 2017, multidrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii were identified by WHO as the highest priority pathogens, which require urgent attention for the discovery of novel antibiotics. Over the last decade, ‘old’ polymyxins are increasingly used as the last defence against these Gram-negative ‘superbugs’ and unfortunately, resistance to polymyxins has been increasingly reported. As no new antibiotics will be available for Gram-negative ‘superbugs’ in the near future, it is crucial to optimise the clinical use of current antibiotics and develop novel therapies.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Pathogenic membranes as therapeutic drug targets Aguilar, M., Reid, G., Separovic, F., Yarovsky, I., Li, J. & Drummer, H. 1/01/22 → 31/12/25 Parallel Extended HDX system (Trajan Scientific and Medical) Schittenhelm, R., Davidovich, C., Purcell, A., Ellisdon, A., Li, J., Aguilar, M., Cryle, M., Stone, M., Lithgow, T. & Zhang, Q. 1/10/21 → 31/12/22 The Monash Phage Foundry Lithgow, T., Li, J., Barr, J., Peleg, A. & Banaszak Holl, M. 1/10/21 → 31/12/22 Towards the Translation of Synergistic Phage-Polymyxin Combination Therapy against Pandrug-resistant Klebsiella pneumoniae: A Systems Approach Li, J., Barr, J., Lin, W., Rao, G. & Schooley, R. T. 16/08/21 → 31/07/23 Infections promote post-traumatic epilepsy and poor outcomes after traumatic brain injury Semple, B., O'Brien, T. & Li, J. United States Department of Defense (DOD) 4/01/21 → 29/09/23 Pharmacology of intrathecal/intraventricular polymyxins: A systems-based approach Rao, G. & Li, J. 1/07/20 → 30/06/24 Integrating AI, Big Data and Smart Drug Design against 'Superbugs' Song, J., Li, J., Patil, N., Schmidt, D. & Thompson, P. 1/01/20 → 31/12/23 A systems approach to combat the significant antibiotic resistance challenge: Novel therapeutic strategies, mechanistic discoveries, and drug development Li, J. National Health and Medical Research Council (NHMRC) (Australia) 1/01/19 → 31/12/23 Integrative systems pharmacology, neutron reflectometry and molecular dynamics approaches to unravelling the interaction between polymyxins and bacterial membranes Li, J., Shen, H., Velkov, T., Song, J. & Schreiber, F. 1/01/18 → 31/12/22 Targeting the Urgent Need for New Antibiotics against Gram-negative ‘Superbugs’Li, J., Velkov, T., Roberts, K., Thompson, P. & Nation, R. 1/08/17 → 31/07/23 Combating Deadly Gram-negative Lung Infections: An Inhalation and Systems Approach Li, J. & Velkov, T. National Institutes of Health (United States) 1/08/17 → 31/07/22 Advancing innovative therapies against pandrug-resistant Gram-negative superbugs Li, J., Zhou, Q., Rao, G., Kaye, K. S. & Velkov, T. National Institutes of Health (United States) 1/07/19 → 30/06/22 Dolomite Single Cell RNA Seq System / 4 CO2 Incubators / Class II Biological Safety Hoods Rosenbluh, S., Firestein, R., Daly, R., Hertzog, P., Mitchell, C., Li, J., Southey, M., Jenkins, B., Ryan, M. & Traven, A. 1/01/18 → 31/12/18 An integrated virtual cell approach towards elucidating the systems pharmacology of antibiotics against Pseudomonas aeruginosa Li, J., Song, J. & Schreiber, F. National Health and Medical Research Council (NHMRC) (Australia) 1/01/17 → 31/12/20 Harnessing bacteriophages as natural predators to combat the superbugs: a pulmonary drug delivery approach Chan, H. & Li, J. 1/12/16 → 30/11/17 Optimising inhaled polymyxins as a vital therapy for pulmonary infections: A novel biochemical, molecular imaging and systems pharmacology approach Li, J., Chan, H., Velkov, T., Zhou, Q. & Zhou, F. National Health and Medical Research Council (NHMRC) (Australia) 1/01/16 → 31/12/18 Optimizing Clinical use of polymyxin B: teaching an old drug to treat superbugs Li, J., Nation, R. & Purcell, A. National Institutes of Health (United States) 19/06/15 → 31/05/21 Targeting the Achilles' heel of polymyxins: eliminating the nephrotoxicity Li, J., Nation, R., Thompson, P. & Velkov, T. National Health and Medical Research Council (NHMRC) (Australia) 1/01/15 → 31/12/17 Virtual cell of Pseudomonas aeruginosa: Paradigm shifting in antibiotic discovery Li, J., Song, J., Schreiber, F., Marriott, K. & Lithgow, T. Monash University – Internal University Contribution 1/01/15 → 21/12/17 New tricks for 'old' drugs:PK/PD of polymyxin nonantibiotic combinations Li, J., Song, J., Forrest, A., Creek, D., Velkov, T., Purcell, A. & Hertzog, P. National Institutes of Health (United States) 1/04/14 → 31/03/19